Timing of Corticosteroids in COVID-19, II. Post COVID-19 Follow-up
Overview
- Phase
- Phase 4
- Intervention
- Early-Corticosteroids
- Conditions
- Covid19
- Sponsor
- ClinAmygate
- Enrollment
- 752
- Locations
- 1
- Primary Endpoint
- Percentage of cases that will need oxygen supplementation
- Status
- Active, not recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
Timing of of corticosteroids administration is very important in COVID19 cases for the recovery and decrease the mortality.
Detailed Description
The sickest patients with COVID-19 suffer a hyperinflammatory state-a cytokine storm-that has features in common with a rare haematological condition called haemophagocytic lymphohistiocytosis. Immune suppression should help such patients. By contrast, immune suppression during the early phase of the viral infection might allow increased viral replication and aggravate the disease. The 3C-like proteinase on SARS-CoV-2 (nsp5) inhibits HDAC2 transport into the nucleus, and so impairs the way in which it mediates inflammation and cytokine responses, so activation of histone deacetylase by dexamethasone may directly oppose the action of SARS-CoV-2. Timing of of corticosteroids administration is very important in COVID19 cases for the recovery and decrease the mortality.
Investigators
Emad R Issak
Dr
ClinAmygate
Eligibility Criteria
Inclusion Criteria
- •any case with COVID-19 more than or equal to 18 years
- •mild and moderate severity
Exclusion Criteria
- •Severe to critical COVID-19
- •Any contra-indication for the interventional drug
- •Mentally disabled cases
Arms & Interventions
Early CS
early use of dexamethasone as early as the laboratory confirmation of inflammation.
Intervention: Early-Corticosteroids
Outcomes
Primary Outcomes
Percentage of cases that will need oxygen supplementation
Time Frame: 10 days
Percentage of cases whose clinical status deteriorate that their sPO2 become less than 92%
Percentage of cases that will need hospitalization
Time Frame: 10 days
Deterioration in the clinical picture of cases that necessitate hospitalization
28-days mortality
Time Frame: 28 days
Percentage of cases who died within 28 days of presentation
Secondary Outcomes
- Percentage of cases with increased d-dimer(10 days)
- Percentages of COVID-19 Severity according to CDC 2020(10 days)
- Time to return to daily activity(60 days)
- Percentage reduction in LDH(10 days)
- Percentage reduction in CRP(10 days)
- Percentage reduction in Ferritin(10 days)